Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31263652 | 1.00 | TSHR (0.56) | TSHRMAPK1CYP3A4CASP1RECQL | |
| SCHEMBL8432403 | 0.86 | TSHR (0.56) | TSHRMAPK1CYP3A4CASP1RECQL | |
| SCHEMBL304190 | 0.83 | ESR1 (0.50) | MAPK1CYP3A4ALDH1A1CA2ESR1 | |
| SCHEMBL29374282 | 0.81 | TSHR (0.60) | TSHRMAPK1CYP3A4CASP1RECQL | |
| SCHEMBL111419 | 0.81 | MAPK1 (0.60) | TSHRMAPK1CYP3A4CASP1RECQL | |
| SCHEMBL29403060 | 0.81 | MAPK1 (0.60) | TSHRMAPK1CYP3A4CASP1RECQL | |
| SCHEMBL125232 | 0.81 | TSHR (0.60) | TSHRMAPK1CYP3A4CASP1RECQL | |
| SCHEMBL31476400 | 0.81 | TSHR (0.60) | TSHRMAPK1CYP3A4CASP1RECQL | |
| SCHEMBL14196693 | 0.81 | TSHR (0.50) | TSHRMAPK1CYP3A4CASP1RECQL | |
| SCHEMBL29467505 | 0.81 | TSHR (0.50) | TSHRMAPK1CYP3A4CASP1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739683-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-3985001-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER | SERVIER LAB (FR) | 2026-04-29 | — | — | EP | disclosed |
| US-20250206730-A1 | THIAZOLE DERIVATIVE COMPOUND AND USES THEREOF | AUTOTELIC BIO INC. (KR) | 2025-06-26 | — | — | US | disclosed |
| WO-2025063816-A1 | COMPOSITION FOR TREATING UTERINE FIBROSIS COMPRISING THIAZOLE DERIVATIVE COMPOUND | 오토텔릭바이오 주식회사 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063820-A1 | COMPOSITION FOR TREATING PULMONARY FIBROSIS COMPRISING THIAZOLE DERIVATIVE COMPOUND | 오토텔릭바이오 주식회사 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063819-A1 | COMPOSITION FOR TREATING FIBROTIC DISEASE COMPRISING THIAZOLE DERIVATIVE COMPOUND | 오토텔릭바이오 주식회사 | 2025-03-27 | — | — | WO | disclosed |
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-4501928-A1 | THIAZOLE DERIVATIVE COMPOUND AND USES THEREOF | Autotelic Bio Inc. (KR) | 2025-02-05 | — | — | EP | disclosed |
| WO-2025008059-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| EP-2085220-A2 | Resin composition for laser engraving, relief printing plate precursor for laser engraving, relief printing plate and method of producing the same | FUJIFILM Corporation (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-20090191479-A1 | RESIN COMPOSITION FOR LASER ENGRAVING, RELIEF PRINTING PLATE PRECURSOR FOR LASER ENGRAVING, RELIEF PRINTING PLATE AND METHOD OF PRODUCING THE SAME | FUJIFILM CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090155247-A1 | Methods of Using Death Receptor Agonists and EGFR Inhibitors | ASHKENAZI AVI J | 2009-06-18 | — | — | US | disclosed |
| EP-1622912-B1 | 2-ALKYNYL-AND 2-ALKENYL-PYRAZOLO- [4,3-E ] -1,2,4-TRIAZOLO- [1,5-C] -PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7390927-B2 | Process for preparing 3-aminophenylacetylenes | FUJILFILM CORPORATION (JP) | 2008-06-24 | — | — | US | disclosed |
| EP-1856053-A1 | CINNAMIDE AND HYDROCINNAMIDE DERIVATIVES WITH RAF-KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006076706-A1 | CINNAMIDE AND HYDROCINNAMIDE DERIVATIVES WITH RAF-KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2005103055-A1 | PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155247-A1 | Methods of Using Death Receptor Agonists and EGFR Inhibitors | EGFR, ERBB4, TNFRSF9 | TSHR 369/4885MAPK1 2182/4885CYP3A4 1789/4885 |
| US-20250206730-A1 | THIAZOLE DERIVATIVE COMPOUND AND USES THEREOF | TGFBR1, TGFBR2, ALK | TSHR 214/4885MAPK1 699/4885CYP3A4 2172/4885 |
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MAP3K21, HIPK4, MAP3K20 | TSHR 4724/4885MAPK1 123/4885CYP3A4 3567/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | TSHR 403/4885MAPK1 2954/4885CYP3A4 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.